Skip to content

Study · Randomized controlled trial · n = 610 · 2025

12 results

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, Zhong S, Han J and 11 more

Show all authors

Zhang Y, Lian Q, Yang P, Lv L, Gu J, Liu Z, Deng H, Wang Y, Li L, Pei L, Qian L

The New England journal of medicine25 May 2025Cited by 88 (Europe PMC)

PMID40421736 (opens in a new tab)DOI10.1056/nejmoa2411528 (opens in a new tab)PepBankPUB-40421736
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, 4 mg mazdutide reduced body weight at week 32 more than placebo.

    In plain wordsIn Chinese adults with obesity or overweight, 4 mg weekly mazdutide led to more weight loss than placebo at week 32.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight percent change at week 32
    Study

    n = 610

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · 32 weeksAs given in this study (human).

    Measurements

    Body weight change
    −10.09%
    mazdutide 4 mg, week 32

    Source sentences

    Summary
    -10.09% (95% confidence interval [CI], -11.15 to -9.04) in the 4-mg mazdutide group
    3 context sentences
    Summary · context
    At week 32, the mean percentage change in body weight from baseline was
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, 6 mg mazdutide reduced body weight at week 32 more than placebo.

    In plain wordsIn Chinese adults with obesity or overweight, 6 mg weekly mazdutide led to more weight loss than placebo at week 32.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight percent change at week 32
    Study

    n = 610

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    6 mg once weekly · 32 weeksAs given in this study (human).

    Measurements

    Body weight change
    −12.55%
    mazdutide 6 mg, week 32

    Source sentences

    Summary
    -12.55% (95% CI, -13.64 to -11.45) in the 6-mg mazdutide group
    3 context sentences
    Summary · context
    At week 32, the mean percentage change in body weight from baseline was
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, more participants had a weight reduction of at least 5% at week 32 with 4 mg mazdutide than with placebo.

    In plain wordsIn Chinese adults with obesity or overweight, more people lost at least 5% of body weight with 4 mg weekly mazdutide than with placebo.

    Peptide
    Mazdutide
    Outcome
    IncreaseWeight reduction of at least 5% at week 32
    Study

    n = 610

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · 32 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=5%
    73.9%
    mazdutide 4 mg, week 32
    Responders with weight reduction >=5%
    10.5%
    placebo, week 32

    Source sentences

    Summary
    73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5%
    2 context sentences
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, more participants had a weight reduction of at least 5% at week 32 with 6 mg mazdutide than with placebo.

    In plain wordsIn Chinese adults with obesity or overweight, more people lost at least 5% of body weight with 6 mg weekly mazdutide than with placebo.

    Peptide
    Mazdutide
    Outcome
    IncreaseWeight reduction of at least 5% at week 32
    Study

    n = 610

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    6 mg once weekly · 32 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=5%
    82%
    mazdutide 6 mg, week 32
    Responders with weight reduction >=5%
    10.5%
    placebo, week 32

    Source sentences

    Summary
    73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5%
    2 context sentences
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, 4 mg mazdutide reduced body weight at week 48 more than placebo.

    In plain wordsIn Chinese adults with obesity or overweight, 4 mg weekly mazdutide led to more weight loss than placebo at week 48.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight percent change at week 48
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −11%
    mazdutide 4 mg, week 48

    Source sentences

    Summary
    -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group
    3 context sentences
    Summary · context
    At week 48, the mean percentage change in body weight from baseline was
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, 6 mg mazdutide reduced body weight at week 48 more than placebo.

    In plain wordsIn Chinese adults with obesity or overweight, 6 mg weekly mazdutide led to more weight loss than placebo at week 48.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight percent change at week 48
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    6 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −14.01%
    mazdutide 6 mg, week 48

    Source sentences

    Summary
    -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group
    3 context sentences
    Summary · context
    At week 48, the mean percentage change in body weight from baseline was
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, more participants had a weight reduction of at least 15% at week 48 with 4 mg mazdutide than with placebo.

    In plain wordsIn Chinese adults with obesity or overweight, more people lost at least 15% of body weight with 4 mg weekly mazdutide than with placebo.

    Peptide
    Mazdutide
    Outcome
    IncreaseWeight reduction of at least 15% at week 48
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=15%
    35.7%
    mazdutide 4 mg, week 48
    Responders with weight reduction >=15%
    2%
    placebo, week 48

    Source sentences

    Summary
    35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15%
    2 context sentences
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, more participants had a weight reduction of at least 15% at week 48 with 6 mg mazdutide than with placebo.

    In plain wordsIn Chinese adults with obesity or overweight, more people lost at least 15% of body weight with 6 mg weekly mazdutide than with placebo.

    Peptide
    Mazdutide
    Outcome
    IncreaseWeight reduction of at least 15% at week 48
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    6 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=15%
    49.5%
    mazdutide 6 mg, week 48
    Responders with weight reduction >=15%
    2%
    placebo, week 48

    Source sentences

    Summary
    35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15%
    2 context sentences
    Summary · context
    (P<0.001 for all comparisons with placebo).
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with obesity or overweight, beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide.

    In plain wordsIn Chinese adults with obesity or overweight, mazdutide showed benefits on all planned heart and metabolic measures.

    Peptide
    Mazdutide
    Outcome
    Direction not reportedPrespecified cardiometabolic measures
    Study

    n = 610

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    4 mg or 6 mg once weekly · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide.
    1 context sentence
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  10. 10HumanRandomized controlled trialSafety outcome

    In Chinese adults with obesity or overweight, the most frequent adverse events with mazdutide were gastrointestinal and mostly mild to moderate.

    In plain wordsIn Chinese adults with obesity or overweight, the most common side effects of mazdutide affected the stomach and bowel and were mostly mild to moderate.

    Peptide
    Mazdutide
    Outcome
    Not applicableMost frequent adverse events
    Study

    n = 610

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    4 mg or 6 mg once weekly · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity.
    1 context sentence
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  11. 11HumanRandomized controlled trialSafety outcome

    In Chinese adults with obesity or overweight, adverse events led to discontinuation in 1.5% with 4 mg mazdutide and 1.0% with placebo; no test is reported.

    In plain wordsIn Chinese adults with obesity or overweight, 1.5% stopped treatment because of side effects with 4 mg weekly mazdutide, compared with 1.0% with placebo.

    Peptide
    Mazdutide
    Outcome
    Not applicableAdverse events leading to discontinuation
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    4 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Discontinuation due to AE
    1.5%
    mazdutide 4 mg
    Discontinuation due to AE
    1%
    placebo

    Source sentences

    Summary
    The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo.
    1 context sentence
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.
  12. 12HumanRandomized controlled trialSafety outcome

    In Chinese adults with obesity or overweight, adverse events led to discontinuation in 0.5% with 6 mg mazdutide and 1.0% with placebo; no test is reported.

    In plain wordsIn Chinese adults with obesity or overweight, 0.5% stopped treatment because of side effects with 6 mg weekly mazdutide, compared with 1.0% with placebo.

    Peptide
    Mazdutide
    Outcome
    Not applicableAdverse events leading to discontinuation
    Study

    n = 610

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg once weekly · 48 weeksAs given in this study (human).

    Measurements

    Discontinuation due to AE
    0.5%
    mazdutide 6 mg
    Discontinuation due to AE
    1%
    placebo

    Source sentences

    Summary
    The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo.
    1 context sentence
    Summary · context
    Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT05607680

A Study of IBI362 in Participants With Obesity or Overweight

Innovent Biologics (Suzhou) Co. Ltd.n = 61014 Nov 2022 to 16 Apr 2024

Obesity Or Overweight

Trial pageClinicalTrials.govUpdated 12 Nov 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.